IQVIA (IQV) Stock Price, News & Analysis

Company Overview

IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.

Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms. IQVIA combines healthcare information with analytics and technology to help customers design studies, evaluate treatments, understand markets, improve patient engagement and support healthcare decision-making.

The company was formed through the 2016 merger of Quintiles Transnational Holdings and IMS Health and adopted the IQVIA name in 2017. Headquartered in Durham, North Carolina, IQVIA serves customers across global markets. Ari Bousbib has served as the company’s chairman and chief executive officer since the merger.

Key Stats

• Today's Range: $269.43 to $274.90
• 50-Day Range: $198.96 to $275.38
• 52-Week Range: $154.50 to $277.40
• Volume: 1.10 million shs
• Average Volume: 1.73 million shs
• Market Capitalization: $44.46 billion
• P/E Ratio: 33.51
• Dividend Yield: N/A
• Price Target: $248.00
• Consensus Rating: Moderate Buy

IQVIA Stock Analysis - MarketRank™

IQVIA scored higher than 54% of companies evaluated by MarketBeat, and ranked 466th out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

IQVIA has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 13 buy ratings, 3 hold ratings, and no sell ratings.

Downside Risk

IQVIA has a consensus price target of $248.00, representing about 8.7% downside from its current price of $271.75.

Amount of Analyst Coverage

IQVIA has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 11.85%

Earnings Growth

Earnings for IQVIA are expected to grow by 11.85% in the coming year, from $11.56 to $12.93 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IQVIA is 33.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.94.

Price to Earnings Ratio vs. Sector

The P/E ratio of IQVIA is 33.70, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.69.

Price to Earnings Growth Ratio

IQVIA has a PEG Ratio of 2.31. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

IQVIA has a P/B Ratio of 6.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.54% of the float of IQVIA has been sold short.

Short Interest Ratio / Days to Cover

IQVIA has a short interest ratio ("days to cover") of 3.05, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IQVIA has recently increased by 8.98%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IQVIA does not currently pay a dividend.

Dividend Growth

IQVIA does not have a long track record of dividend growth.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: 0.42

News Sentiment

IQVIA has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for IQVIA this week, compared to 7 articles on an average week.

Search Interest

Only 2 people have searched for IQV on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added IQVIA to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, IQVIA insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,796,021.00 in company stock.

Percentage Held by Insiders

1.70% of the stock of IQVIA is held by insiders.

Percentage Held by Institutions

89.62% of the stock of IQVIA is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/28/2026
• Today: 9/25/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NYSE:IQV
• CIK: 1478242
• Web: www.iqvia.com
• Phone: (919) 998-2000
• Fax: N/A
• Employees: 93,000
• Year Founded: 2016

Price Target and Rating

• Average Price Target for IQVIA: $248.00
• High Price Target: $288.00
• Low Price Target: $185.00
• Potential Upside/Downside: -8.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): $8.06
• Trailing P/E Ratio: 33.51
• Forward P/E Ratio: 23.37
• P/E Growth: 2.31
• Net Income: $1.36 billion
• Net Margins: 8.10%
• Pretax Margin: 9.27%
• Return on Equity: 30.25%
• Return on Assets: 6.54%

Debt

• Debt-to-Equity Ratio: 2.18
• Current Ratio: 0.71
• Quick Ratio: 0.71

Sales & Book Value

• Annual Sales: $16.31 billion
• Price / Sales: 2.73
• Cash Flow: $17.87 per share
• Price / Cash Flow: 15.12
• Book Value: $38.93 per share
• Price / Book: 6.94

Miscellaneous

• Outstanding Shares: 164,600,000
• Free Float: 161,802,000
• Market Cap: $44.46 billion
• Optionable: Optionable
• Beta: 1.18